While much of CRISPR research has focused on genome editing, numerous discoveries have been made using the Cas9 nuclease in the absence of genomic alterations. These studies utilize a catalytically inactive form of Cas9 known as dCas9 (Jinek et al., 2012). Like Cas9, dCas9 can bind to a specific DNA sequence via a targeting gRNA. But dCas9 does not cleave the DNA. Much of the research using dCas9 has focused on transcriptional activation using a fusion to a transcriptional activator such as VP64 (Gilbert et al., 2013), or repression of transcription through binding a promoter region to inhibit association of transcriptional activators (Qi et al., 2013). However, the fusion of dCas9 with a protein tag allows for the isolation of a genomic region of interest targeted by a gRNA.